Open Access

MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma

  • Authors:
    • Ye Dong
    • Jianjun Zou
    • San Su
    • Huiyi Huang
    • Yanzhen Deng
    • Birong Wang
    • Weidong Li
  • View Affiliations

  • Published online on: March 19, 2015     https://doi.org/10.3892/mmr.2015.3516
  • Pages: 1016-1022
  • Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer type worldwide and the third leading cause of cancer-associated mortality. To date, its pathogenesis has remained poorly understood. Previous studies have demonstrated that deregulated microRNA (miR) participates in hepatocarcinogenesis. In the present study, miR‑218 and miR‑520a were observed to be downregulated in human HCC cells relative to normal hepatic cells. Overexpression of miR‑218 or miR‑520a inhibited cell proliferation and induced cell cycle arrest at the G0/G1 phase checkpoint. Furthermore, a dual‑luciferase reporter assay identified that E2F2 was a novel direct target of miR‑218 but not miR‑520a in HCC. In addition, miR‑218 and miR‑520a were observed to negatively regulate E2F2 mRNA and protein levels. This suggested that miR‑218 regulated the expression of E2F2 via directly binding to its 3'‑untranslated region, whereas miR‑520a affected E2F2 expression indirectly. In conclusion, these results indicated that miR‑218 and miR‑520a are crucial in the development of HCC via the inhibition of cell proliferation and cycle progression by downregulating E2F2.

References

1 

Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI

2 

Baker AH and van Rooij E: miRNA overexpression induces cardiomyocyte proliferation in vivo. Mol Ther. 21:497–498. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Heinzelmann J, Henning B, Sanjmyatav J, et al: Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol. 29:367–373. 2011. View Article : Google Scholar : PubMed/NCBI

4 

Zhang JF, Fu WM, He ML, et al: MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling. RNA Biol. 8:829–838. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI

6 

Ventura A and Jacks T: MicroRNAs and cancer: short RNAs go a long way. Cell. 136:586–591. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Bosch FX, Ribes J, Díaz M and Cléries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology. 127:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI

8 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

9 

El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI

10 

Giordano S and Columbano A: MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 57:840–847. 2013. View Article : Google Scholar

11 

Augello C, Vaira V, Caruso L, et al: MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int. 32:772–782. 2012. View Article : Google Scholar : PubMed/NCBI

12 

Garofalo M, Di Leva G, Romano G, et al: miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 16:498–509. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Gramantieri L, Ferracin M, Fornari F, et al: Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 67:6092–6099. 2007. View Article : Google Scholar : PubMed/NCBI

14 

Kota J, Chivukula RR, O’Donnell KA, et al: Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 137:1005–1017. 2009. View Article : Google Scholar : PubMed/NCBI

15 

Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Zhu Y, Lu Y, Zhang Q, et al: MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res. 40:4615–4625. 2012. View Article : Google Scholar : PubMed/NCBI

17 

Alajez NM, Lenarduzzi M, Ito E, et al: MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 71:2381–2391. 2011. View Article : Google Scholar : PubMed/NCBI

18 

Gao CP, Zhang Z, Liu W, Xiao S, Gu W and Lu H: Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer. 116:41–49. 2010.

19 

Li Q, Zhu F and Chen P: miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer. Biochem Biophys Res Commun. 424:28–33. 2012. View Article : Google Scholar : PubMed/NCBI

20 

Liu Y, Yan W, Zhang W, et al: MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. Oncol Rep. 28:1013–1021. 2012.PubMed/NCBI

21 

Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP and Khan SA: Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene. 27:2575–2582. 2008. View Article : Google Scholar :

22 

Uesugi A, Kozaki K, Tsuruta T, et al: The tumor suppressive microRNA miR-218 targets the mTOR component rictor and inhibits AKT phosphorylation in oral cancer. Cancer Research. 71:5765–5778. 2011. View Article : Google Scholar : PubMed/NCBI

23 

White NMA, Bao TT, Grigull J, et al: miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol. 186:1077–1083. 2011. View Article : Google Scholar : PubMed/NCBI

24 

Wu DW, Cheng YW, Wang J, Chen CY and Lee H: Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res. 70:10392–10401. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Li C, Tu K, Zheng X, et al: MicroRNA-218 expression and its role in hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 33:1127–1131. 2013.In Chinese. PubMed/NCBI

26 

Ye W, Yao Q, Zhang M, Wen Q and Wang J: miR-520a regulates ErbB4 expression and suppresses proliferation and invasion of esophageal squamous cell carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 34:164–168. 2014.In Chinese. PubMed/NCBI

27 

Attwooll C, Lazzerini Denchi E and Helin K: The E2F family: specific functions and overlapping interests. EMBO J. 23:4709–4716. 2004. View Article : Google Scholar : PubMed/NCBI

28 

Dimova DK and Dyson NJ: The E2F transcriptional network: old acquaintances with new faces. Oncogene. 24:2810–2826. 2005. View Article : Google Scholar : PubMed/NCBI

29 

Ren B, Cam H, Takahashi Y, et al: E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev. 16:245–256. 2002. View Article : Google Scholar : PubMed/NCBI

30 

Chen C and Wells AD: Comparative analysis of E2F family member oncogenic activity. PLoS ONE. 2:e9122007. View Article : Google Scholar : PubMed/NCBI

31 

Santoni-Rugiu E, Jensen MR and Thorgeirsson SS: Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res. 58:123–134. 1998.PubMed/NCBI

32 

Zhan L, Huang C, Meng XM, et al: Promising roles of mammalian E2Fs in hepatocellular carcinoma. Cell Signal. 26:1075–1081. 2014. View Article : Google Scholar : PubMed/NCBI

33 

Dong Q, Meng P, Wang T, et al: MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS ONE. 5:e101472010. View Article : Google Scholar : PubMed/NCBI

34 

He XQ, Dong YJ, Wu CW, et al: MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol Med. 18:1491–1498. 2012.PubMed/NCBI

Related Articles

Journal Cover

July 2015
Volume 12 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Dong, Y., Zou, J., Su, S., Huang, H., Deng, Y., Wang, B., & Li, W. (2015). MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma. Molecular Medicine Reports, 12, 1016-1022. https://doi.org/10.3892/mmr.2015.3516
MLA
Dong, Y., Zou, J., Su, S., Huang, H., Deng, Y., Wang, B., Li, W."MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma". Molecular Medicine Reports 12.1 (2015): 1016-1022.
Chicago
Dong, Y., Zou, J., Su, S., Huang, H., Deng, Y., Wang, B., Li, W."MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma". Molecular Medicine Reports 12, no. 1 (2015): 1016-1022. https://doi.org/10.3892/mmr.2015.3516